Allergenic Products Advisory Committee meeting
Executive Summary
A proposed strategy for the reclassification of Category IIIA allergenic products - those for which data are insufficient for classification but which are thought to have a favorable risk-benefit ratio and should remain on the market pending completion of testing - will be discussed at the Sept. 13 meeting of FDA's Allergenic Products Advisory Committee. In its 2005 meeting, the committee had advised FDA to expand its data search boundaries for the reclassification of Category IIIA allergenic extracts (1"The Pink Sheet" April 11, 2005, p. 36). The meeting, to be held at the National Institutes of Health, Bethesda, Md. from noon to 3:45 p.m., will include an update of CBER's Laboratory of Immunobiochemistry's research program on parasitic and allergenic products...